DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2018" report has been added to ResearchAndMarkets.com's offering.
The Global Gene Therapy Partnering Agreements 2010-2018 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.
Report scope
Global Gene Therapy Partnering Terms and Agreements includes:
- Trends in gene therapy dealmaking in the biopharma industry since 2010
- Analysis of gene therapy deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life gene therapy deals
- Access to over 200 gene therapy deals
- The leading gene therapy deals by value since 2010
- Most active gene therapy dealmakers since 2010
- The leading gene therapy partnering resources
In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
For more information about this report visit https://www.researchandmarkets.com/research/8zt8j4/global_gene?w=4
